Upgrade to SI Premium - Free Trial

Jefferies Downgrades Esperion Therapeutics (ESPR) to Hold, PT to $3.28

May 1, 2026 3:15 PM
Jefferies analyst Dennis Ding downgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Hold with a price target of $3.28 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades